|Bid||56.60 x 800|
|Ask||56.60 x 800|
|Day's Range||55.68 - 56.72|
|52 Week Range||34.69 - 58.14|
|Beta (3Y Monthly)||0.95|
|PE Ratio (TTM)||32.15|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||0.19 (0.36%)|
|1y Target Est||58.60|
Ensign Group Inc NASDAQ/NGS:ENSGView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ENSG with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ENSG. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ENSG are favorable, with net inflows of $1.59 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Acadia Healthcare's strong presence in the growing behavioral healthcare business with solid fundamentals has helped the stock to rally.
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Ensign Group (ENSG) purchases the assets of Preceptor Health Care and the real estate and operations of Golden Palms Rehabilitation and Retirement.
MISSION VIEJO, Calif., June 05, 2019 -- The Ensign Group, Inc. (NASDAQ: ENSG), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, home.
Ensign Group (ENSG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MISSION VIEJO, Calif., June 05, 2019 -- The Ensign Group, Inc. (NASDAQ: ENSG), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, home.
One of the painful but crucial lessons that the re-escalating trade war has taught us is that anything can happen. Just a few weeks ago, a resolution between the U.S. and China appeared an inevitability. Now, even the idea of getting together for talks is questionable. That said, not all stocks to buy are vulnerable to unexpected sentiment shifts.If you're seeking a market segment that will likely produce strong gains over the next decade, it's time to look at assisted-living stocks. Elderly care operates on two core principles. First, it's our moral and ethical obligation to help those that cannot help themselves. Second, aging happens to everyone. Therefore, these specialized-care facilities will essentially exist forever.Other fundamental factors support the case for assisted-living stocks to buy. The biggest tailwind is the sheer size of the baby boomer demographic. Between 1946 and 1964, the U.S. experienced 76 million births. By 2012, 11 million of this generation had died, but that still leaves 65 million survivors. That's a lot of folks that will seek care during their golden years.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMoreover, advancing technologies in medicine and nutrition have noticeably increased our ability to extend our life. True, life expectancy is falling in this country. However, much of that can be attributed to the opioid crisis, which largely affects younger Americans. Overall, though, the point stands: healthcare innovations have had a net positive impact on baby boomers, which in turn affects assisted-living stocks to buy. * 7 Stocks to Buy that Lost 10% Last Week Best of all, the demand exists irrespective of economic or market conditions. It's an area that politically, Washington power-brokers cannot simply gloss over. Unlike discretionary sectors, specialized care levers a very human face. With that, here are seven assisted-living stocks to buy: Welltower (WELL)One of the attributes that attracted me to Welltower (NYSE:WELL) was that it's among Fortune's most admired companies of 2019. From a PR perspective, that's a huge story. As you probably know, assisted-living stocks don't enjoy the greatest of reputations due to scandalous stories of senior abuse.But as an investor, WELL stock provides many other substantive points to chew on. Primarily, shares have performed admirably this year, gaining over 18% since the January opener. Not only that, WELL recovered quickly from last year's broader market selloff. It ended 2018 with a return of 15%, whereas many other companies floundered.If that doesn't convince you to put WELL among your list of stocks to buy, consider its dividend. With a 4.4% yield, this can provide comfortable support should the markets experience a downturn. Ensign Group (ENSG)If you want pure exposure to assisted-living stocks to buy, take a good look at Ensign Group (NASDAQ:ENSG). Headquartered in Mission Viejo, California, ENSG stock is levered toward a robust local economy. Moreover, it offers comprehensive solutions for the elderly, including in-house therapy and hospice care.As with Welltower, ENSG stock exhibits tremendous resilience, even in the face of troubling market conditions. It absorbed a sharp blow during the broader selloff in late 2018. However, shares quickly bounced back. By the second half of February, ENSG had recovered all of its prior losses and then some. * 10 Baby Boomer Stocks to Buy That said, Ensign Group's equity is more representative of growth names than say dividend stocks to buy. For instance, ENSG is up 49% year-to-date, but only offers a miniscule 0.33% yield. Still, if you want to bet on extremely favorable demographics, Ensign is a great idea. Omega Healthcare Investors (OHI)Another strong name among assisted-living stocks to buy is Omega Healthcare Investors (NYSE:OHI). After working through some operational issues, management started this year off on an aggressive footing. In the first quarter, Omega bought out MedEquities Realty Trust (NYSE:MRT), which should boost the operational profile of OHI stock.However, you wouldn't guess that Omega was running on less than 100% of its cylinders by looking at its chart. On a year-to-date basis, OHI stock is up slightly over 15%. Last year, shares returned 40%. As you might imagine, the company hardly blinked during the recent downturn.I expect more of the same should the economy go sour due to a prolonged U.S.-China trade war. Recent quarterly revenues suggest that management is likely to overcome miscues from the past. Also, OHI stock pays out a very generous 7% dividend yield, which should attract shelter-seeking investors. HCP (HCP)A key advantage in acquiring assisted-living stocks to buy is their inverse correlation to current market conditions. For instance, while the benchmark S&P 500 index is down roughly 2% this month, senior-care specialist HCP (NYSE:HCP) has gained almost 7%.It was the same story last year. In the final quarter of 2018, the S&P 500 dropped 10%. On the other hand, HCP stock shot up just under 10% over the same time frame.I expect a similar dynamic if the markets slow down due to trade-war related complications. As with the other organizations in this segment, HCP stock will enjoy consistent, if not growing demand. Furthermore, HCP levers wider coverage of the healthcare sector, including life science, hospital and medical-office properties. * 7 A-Rated Healthcare Stocks for Industry Expansion Finally, HCP pays out a generous 4.7% dividend. Typically, income-generating companies fare better than pure growth names during a bear market. That's one more reason to put HCP in your list of stocks to buy! National HealthCare (NHC)Admittedly, some of the top names among assisted-living stocks represent speculation toward a corporate turnaround. What I like about National HealthCare (AMEX:NHC), though, is their "steady as she goes" financials. For instance, over the past four years, revenue for NHC stock has grown consecutively. This trend continued up to its most recent first quarter of 2019 earnings report.Granted, the growth rate isn't anything to write home about, which is essentially low single digits. But with the massive demographic tailwind that NHC stock benefits from, I'm not sure if they need crazy growth. Approximately 10,000 baby boomers retire each day, which will eventually translate to a robust clientele.Plus, National HealthCare pays out a 2.6% dividend yield. While the payout isn't as attractive as some of the other stocks to buy that I mentioned, the company's upwardly trekking sales is a significant positive. Capital Senior Living (CSU)While assisted-living stocks generally have a boring reputation -- how many of you got really jazzed about this segment? -- not all sector players fit that description. If you're the type to mix your gambling with elderly care, Capital Senior Living (NYSE:CSU) may be right for you.However, I don't want to mislead you in any way: CSU stock is one of the riskiest investments, both in assisted living and the broader markets. Last year was particularly awful for the organization, which suffered from slowing revenues and widening net-income losses. This dynamic was unhelpful to its overbearing long-term debt, to say the least. * 10 Stocks to Sell Before They Tank Your Portfolio Still, some hope exists for a turnaround. Revenue in Q1 was in line with the year-ago haul, suggesting that the sales bleed has stopped. Also, CSU stock has stabilized since hitting rock-bottom in March. It's super-risky, but that's sort of the point. Brookdale Senior Living (BKD)Brookdale Senior Living (NYSE:BKD) is a contradiction. On one hand, it levers the fundamentals that should make BKD stock a top player in the markets. Despite many troubled years, Brookdale is still the nation's top senior-housing owner and operator.But on the other hand, we've got to talk about those troubles. Since 2016, Brookdale's annual revenue has declined consecutively. Even worse, its Q1 2019 sales haul of $1 billion slipped more than 12% year-over-year. It has a sizable debt load and its net-income losses have widened considerably over the years.As a result, BKD stock has fallen into the dumps. But if you're a diehard contrarian, Brookdale may have something for you. Again, it's the top senior-housing operator in America. When you factor in the baby boomer demographic wave, BKD might make some big surprises.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Stocks to Sell Before They Tank Your Portfolio * Top 7 Dow Jones Stocks of 2019 -- So Far * 5 Low-Priced, High-Potential Tech Stocks to Buy Compare Brokers The post 7 Assisted-Living Stocks to Buy Now appeared first on InvestorPlace.
According to the Centers for Medicare and Medicaid Services, healthcare spending will rise 5.5% annually through 2026, when that spending will represent 20% of the country's GDP; a boon for healthcare stocks.To put this in perspective, the U.S. defense budget is about 18% of the entire U.S. budget and we outspend every other nation on this planet in defense spending by a significant margin.The U.S. healthcare system is being debated again and may well be a significant issue in the upcoming presidential election.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut the reality is, the U.S. population is getting older and that means more chronic diseases begin to take their toll. Also, older people tend to take up a larger portion of healthcare costs as their health begins to fail. * 7 High-Yield REITs to Buy (Even When the Market Tanks) That means there will be an unstoppable growth trend in place for healthcare companies. The A-rated healthcare stocks I feature here are well placed to take advantage of this trend. And they're small enough that their growth will outpace their larger competitors and may make them interesting takeover targets.Source: Flickr Masimo (MASI)Masimo Corp (NASDAQ:MASI) is the perfect example of how technology is transforming healthcare.Once, heading the doctors or the hospital was a regular occurrence for patients with chronic issues like heart disease or diabetes. But now, monitoring technologies, where patients can wear a device that essentially tracks their functions and the data can either be downloaded remotely or by the patient and sent to the doctor, are becoming increasingly common.And MASI is one of the leaders in the field. It is also one of the two top players in the pulse oximetry sector. These are devices that check the oxygen saturation level a person's blood. Hospitals use these a great deal and generally the contracts run on a five-year basis, so income is steady and once they're in place it's unlikely the hospitals will switch over to a new type of unit, so there are solid competitive moats.MASI is up almost 44% in the past 12 months, and much of that has come in 2019. This is the kind of company that can grow with the market regardless of what U.S. healthcare ends up looking like.Source: Shutterstock Ionis Pharmaceuticals (IONS)Ionis Pharmaceuticals (NASDAQ:IONS) was founded by leading biotech scientists to expand the use of antisense therapy. It's a new form of treatment that is at the cutting edge of science medicine.Basically, if you can find a genetic marker for a disease, you can synthesize a strand of RNA that can render that gene inactive, so it doesn't reproduce. The potential uses extend to cancers, heart disease, diabetes, asthma, arthritis … the list goes on. * 6 Chinese Stocks That Could Pop On a Trade Deal This technology has the potential to help both rare and common maladies, many of which don't have current effective treatments.IONS is already partnered with a number of larger pharmaceutical firms and is up 55% in the past year, with plenty of headroom left.Source: Shutterstock Osiris Therapeutics (OSIR)Osiris Therapeutics (NASDAQ:OSIR) has a market cap around $650 million, so it's in that perfect spot where it has the potential for big growth on its own, or it could be a target for takeover at a nice premium for a larger pharma looking for a unique product line.OSIR specializes in regenerative medicine products. What that means is, it uses stem cells to build medicines that help everything from wound healing to bone marrow graft acceptance. It's a unique space that has significant possibilities now and for the future.It currently has five products on the market that are focused on wound healing, ligament repairs and surgical wraps on tissues. All promote better healing outcomes with less infections than traditional methods.Last quarter it sold the rights to one of its top stem cell drug for $100 million, so it's work is being recognized. OSIR stock is up 141% for the year and 40% in 2019.Source: Shutterstock Ensign Group (ENSG)Ensign Group (NASDAQ:ENSG) specializes in post-acute care staffing for a wide variety of facilities that would need these services. Some of the most obvious would be assisted living facilities, home health care, rehab facilities and hospice. It manages 250 companies in more than 12 states, around the U.S.This is precisely the sort of sector that will be in huge demand in coming years. While all the technology and new drugs are great, there will still need to be qualified people helping support the patients as they recover and attempt to maintain active lifestyles. * 10 Retirement Stocks That Won't Wilt in a Bear Market It continues to expand its base in California, where the company is headquartered, having just bought another company in Southern California. But its operations beyond the state show that it has what it takes to expand its model where the most opportunity is.Up 59% in the past year, its size makes it a potential takeover target or a big grower on its own.Source: Shutterstock Genomic Health (GHDX)Genomic Health (NASDAQ:GHDX) specializes in genomic diagnostic testing, specifically for cancer. The testing allows for patients and doctors to create individualized treatment strategies for patients.This is important because it means patients get the treatment they need -- they're not over-treated or under-treated. And that is good for the whole healthcare system as well as the patients.Again, this kind of diagnostic tool will be something that insurers, hospitals and patients can get behind since it allows care to better suited to each patient with the goal of lowering costs and improving outcomes.The stock is up over 38% in the past year and it's still going strong.Source: Shutterstock National Research Corp (NRC)National Research (NASDAQ:NRC) is all about delivering all the best possible outcomes for patients with their healthcare providers. NRC sees the current and future healthcare sector as patient-driven, and that is not the traditional model.The patient wasn't much more than a bundle of symptoms that were inserted into the healthcare machines to get repaired and sent back out into the world before. Now, it's about creating an experience that not only serves the patient better, but is able to deliver better outcomes and fewer return visits. It's looking at numbers that view the system more holistically.And NRC provides those numbers from its research. * 7 Cloud Stocks to Buy on Overcast Days While it has been around since 1981, NRC is just coming into its own. And it would be a great takeover target for one of the big healthcare insurers or a large hospital chain.Up 26% in the past year, NRC also delivers a nearly a 2% dividend.Source: Shutterstock AngioDynamics (NASDAQ:ANGO) is a medical device company that specializes in equipment that's used for vascular access, surgery, vascular disease and oncology. It actually made a new acquisition earlier this year to increase its oncology suite of products.Specialty medical device makers are in particular demand globally, since the good ones tend to get most of the business. Medicine is a very conservative practice and tested and true is much more preferable to new and interesting.And generally that's the view from hospitals, insurers and patients. It takes years to put new equipment in place and generally the new equipment is from a trusted equipment maker and not the kid on the block. Having been around since 1988, ANGO fits that bill.Although its global potential looks huge as China looks to upgrade its entire healthcare system, it's been volatile over the last year and relatively flat (actually down .3%). Most of the volatility is trade war related and that can't last forever.Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor, Breakthrough Stocks, Accelerated Profits and Platinum Growth. His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Low-Priced Tech Stocks With Great Potential * 9 Stocks That Would Be Hurt By a Mexico/U.S. Border Closure * The Era of Car Ownership Is Over. And These 4 Charts Prove It Compare Brokers The post 7 A-Rated Healthcare Stocks for Industry Expansion appeared first on InvestorPlace.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Ensign Group (ENSG) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Does Ensign Group (ENSG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ensign Group (ENSG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Ensign Group (ENSG) delivered earnings and revenue surprises of 1.85% and -1.27%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Mission Viejo, California-based company said it had profit of 49 cents per share. Earnings, adjusted for one-time gains and costs, were 55 cents per share. The results exceeded Wall Street expectations. ...
The Pennant Group, Inc., which will include Ensign’s home health and hospice operations, substantially all of Ensign’s senior living operations, and Ensign’s mobile diagnostic and clinical laboratory operations. Ensign plans to effect the strategic separation through a spin-off in which it will distribute shares of Pennant’s common stock to Ensign’s shareholders on a pro rata basis. At the time of the spin-off, it is anticipated that Pennant, which is currently a wholly-owned subsidiary of Ensign, will consist of 60 home health and hospice agencies, 51 senior living operations, and mobile diagnostics and lab operations located across 13 states.